AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06165913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early implant placement (type III)
Description: in group 2, Tooth extraction will be performed with care to preserve alveolar bone walls. After 12-16 weeks from tooth extraction, dental implant will be placed.
Study NCT05682729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book Reading Intervention
Description: Children read books containing relevant stimuli.
Study NCT05682729 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Book Reading Intervention
Description: Children read books containing relevant stimuli.
Study NCT05682729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book Reading Intervention
Description: Children read books containing relevant stimuli.
Study NCT05491395 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Hypofractionation scheme will comprise 40 Gy in 15 fractions
Study NCT05817812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa
Description: Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Study NCT04792398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinumtoxin A (BTX A) Xeomin®
Description: Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)
Study NCT04292080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (TECFIDERA™)
Description: Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
Study NCT04292080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No active : no treatment
Description: 30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
Study NCT06033677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial artery cannulation
Description: Interventional application for invasive blood pressure monitoring
Study NCT06033677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Forearm radial artery cannulation
Description: Interventional application for invasive blood pressure monitoring
Study NCT05148832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Systemic Corticosteroid
Description: 10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.
Study NCT06231290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adult full pulpotomy procedure
Description: The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
Study NCT06231290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult full pulpotomy procedure
Description: The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
Study NCT05784662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Workers Addressing Firearm Risk
Description: Educational intervention for social workers.
Study NCT05453981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention
Description: Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
Study NCT04401553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalosporin
Description: First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
Study NCT04401553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second tier antibiotic (Vancomycin)
Description: Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
Study NCT04930458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride
Description: Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months
Study NCT04930458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride with casein phosphopeptides amorphous calcium phosphate
Description: Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months
Study NCT04930458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish
Description: Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months
Study NCT05921760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: ivosidenib taken once daily
Study NCT05921760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recommended Combination Dose (RCD) of ivosidenib
Description: The RCD of ivosidenib taken once daily
Study NCT05921760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab taken by intravenous infusion
Study NCT05921760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab taken by intravenous infusion
Study NCT05348876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: 600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
Study NCT06348537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Polyphenols
Description: Patients with fibromyalgia of Group 1 will consume Olive Polyphenols daily during 60 days.
Study NCT06348537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with fibromyalgia of Group 2 will consume a placebo daily during 60 days.
Study NCT05467735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.
Description: Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
Study NCT04259775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated Insulin Dose Adjustment
Description: The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
Study NCT04259775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Care - change in therapy settings effected at regularly scheduled patient visits
Study NCT06343337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman
Description: Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).
Study NCT06343337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman
Description: Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).
Study NCT06410846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopSpin360
Description: Neck strength and conditioning device used during neck strengthening program.
Study NCT06410846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Strengthening Exercise Plan
Description: Physical therapist designed neck strengthening program.
Study NCT04958161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
Study NCT04723407 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Questionnaire completion
Study NCT06245798 — intervention group
Intervention type: PROCEDURE
Intervention: transarterial chemoembolisation
Description: During transarterial chemoembolisation（TACE）, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function
Study NCT06212570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeySuite
Description: KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.
Study NCT05513768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: level of myosin binding protein c in serum
Description: Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.
Study NCT05450406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
Study NCT06730932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
Description: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Study NCT05695820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training
Description: It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet
Study NCT05233579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
Study NCT04923945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
Study NCT05009199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-444
Description: Subjects will undergo PET imaging using \[18F\]MNI-444.
Study NCT04745845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'A' ) in fluid responsive position
Study NCT04745845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'A') in non-fluid responsive position
Study NCT04745845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'B') in fluid responsive position
Study NCT04745845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'B') in non-fluid responsive position
Study NCT05473936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker led curriculum
Description: The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
Study NCT05421767 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nerve stimulation guided renal denervation procedure
Description: RNS-in
Study NCT05421767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve stimulation guided renal denervation procedure
Description: RNS-in
Study NCT05421767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve stimulation guided renal denervation procedure
Description: RNS-in
Study NCT06131775 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: One blood sample of 10mL is realized before initiation of immunotherapy
Study NCT06131775 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Three blood samples of 10mL are realized at distinct steps of patients disease management : one before the curative surgery, one after three months and one after six months.
Study NCT05196880 — intervention group
Intervention type: DEVICE
Intervention: MolecuLight DX Imaging Device
Description: The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
Study NCT05061901 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lisinopril tablet 20 mg
Description: Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
Study NCT05061901 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zestril® tablet 20 mg
Description: Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
Study NCT05299762 — intervention group
Intervention type: DEVICE
Intervention: INFUSE™ Bone Graft
Description: Ministry of Food and Drug Safety (MFDS) has approved the INFUSE™ Bone Graft for anterior (ALIF) or oblique (OLIF) lumbar interbody spine fusion as a substitute for autogenous bone graft for patients with degenerative disc disease (DDD) who have had at least 6 months of non-operative treatment for this condition.
Study NCT06356324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Participants assigned to 20 minutes of music listening
Study NCT06356324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Television Intervention
Description: Participants assigned to 20 minutes of television viewing
Study NCT05920863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
Study NCT04808414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX9003 for IV Infusion
Description: antibiotic
Study NCT04808414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for IV infusion
Description: Placebo comparator
Study NCT06074627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Placebo Control Form 1
Description: Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
Study NCT05920863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, Lenvatinib
Description: Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day.
Study NCT03219450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: It stimulates the immune system to attack cancer cells.
Study NCT05750589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-101
Description: IRX-101 is a novel ocular anti-septic
Study NCT05750589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Providone-Iodine
Description: 5% Providone-Iodine
Study NCT03219450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
Study NCT03219450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.
Study NCT05401370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue dye
Description: For MB group, the staining of the glandular tissue will be obtained with 3-4 mL of 1% MB that will be introduced into the gland via the salivary duct several minutes before the surgery.The trans-oral catheterization of the Stensen's duct will be performed and the solution will be injected via intravenous cannula.The glandular tissue will turn dark blue.
Study NCT04983979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: sachets of 5g or 10g given OD titrated to serum potassium
Study NCT04983979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo given titrated according to potassium at a dose to 5 or 10g
Study NCT06316505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene motivation with individual oral photograps
Description: Oral photograps was taken at control sessions.
Study NCT06074627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 1.1 Usage
Description: Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.